贝利尤单抗在儿童期起病系统性红斑狼疮中的法国多中心回顾性真实世界研究
治疗6个月时SLEDAI无显著下降,但激素用量呈下降趋势、低疾病活动度比例上升,关节表现改善明显,皮肤、肾脏和血液学应答有限,安全性总体良好。
要点
- 贝利尤单抗治疗6个月对jSLE关节表现改善明显,77.8%达完全缓解。
- 激素用量呈下降趋势(0.53 vs 0.15 mg/kg/day),低疾病活动度比例由6.3%升至37.5%。
- 皮肤、肾脏及血液学应答有限,总体耐受良好,1例因精神症状停药。
核心结论
- 贝利尤单抗(多经静脉给药)对jSLE关节受累有效并具激素节约效应,安全性良好,但对皮肤、肾脏和血液学表现疗效有限。
主要发现
- 6个月时SLEDAI评分无显著下降,但激素用量呈下降趋势(0.53 vs 0.15 mg/kg/day),低疾病活动度比例由6.3%升至37.5%。
- 关节表现明显改善,77.8%达完全缓解;皮肤、肾脏和血液学应答有限。
- 治疗总体耐受良好,1例因精神症状停药。
临床怎么用
- 在jSLE中可考虑贝利尤单抗用于关节受累并辅助减少激素用量,但需关注皮肤、肾脏及血液学表现应答有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Juvenile-onset systemic lupus erythematosus (jSLE) is a rare autoimmune disease. Belimumab, a monoclonal antibody targeting soluble B-lymphocyte stimulator, has been approved for paediatric use in France since 2020. This retrospective, multicentre study aimed to descriptively evaluate the real-world use, efficacy and safety of belimumab after 6 months of treatment in jSLE patients. METHODS: Patients were diagnosed with SLE according to the 2019 EULAR/ACR criteria, and belimumab therapy (intravenous or subcutaneous) was initiated before age 18. Efficacy was assessed using clinical (SLEDAI, low disease activity status, corticosteroid dose) and biological parameters (anti-dsDNA, complement, proteinuria), along with qualitative and semi-quantitative symptom analysis. RESULTS: Twenty-one patients were included. The majority received intravenous belimumab (90.5%) for articular (66.7%) or cutaneous (23.8%) manifestations. At 6 months, SLEDAI scores showed no significant reduction, although there was a trend towards lower corticosteroid use (0.53 vs 0.15 mg/kg/day) and an increase in the proportion of patients achieving low disease activity status (6.3% vs 37.5%). Marked improvement was observed in articular manifestations with 77.8% achieving complete resolution. Cutaneous, renal and haematological responses were limited. Overall, treatment was well tolerated, though psychiatric symptoms led to treatment discontinuation in one patient. CONCLUSION: This retrospective, multicentre study found that belimumab, primarily administered intravenously, was effective for articular involvement and had a corticosteroid-sparing effect in jSLE, with a favourable safety profile. Its efficacy was limited for cutaneous, renal and haematological manifestations. These findings support the potential benefit of belimumab in this population while highlighting the need for prospective, multicentre and long-term studies to confirm these observations.
引用
- Bigey-Frau D, Leguevaques D, Reumaux H, et al. Belimumab use in paediatric-onset systemic lupus erythematosus: a status report in France from a retrospective multicentre descriptive study. Rheumatology (Oxford). 2026. PMID: 42036845. doi:10.1093/rheumatology/keag229
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。